Biblio Discovery — Demo Discovery Service

9 hasil untuk "Brian Higgins"

Menampilkan 1–9 · 0,29 detik · RSS

  1. Artikel Jurnal

    Supporting Early and Ongoing University Student Experiences Through ‘Academic Skills Adviser’ Services

    Brian Higgins; Margot Reeh; Peter Cahill dkk.

    JANZSSA, Vol. 23 No. 2 · 2015 · Inggris · DOAJ Scopus

    Academic support for first year students is critical for improving engagement, retention and completion rates at one of Australia’s smallest but fastest-growing universities. A model of Academic Skills Adviser (ASA) support developed over recent years at the University of the Sunshine Coast (USC)…

  2. Artikel Jurnal Teks lengkap

    BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.

    Brenden Chen; Christine Tardell; Brian Higgins dkk.

    PLoS ONE, Vol. 7 No. 8 · 2012 · Inggris · DOAJ Scopus

    Cross-feedback activation of MAPK and AKT pathways is implicated as a resistance mechanism for cancer therapeutic agents targeting either RAF/MEK or PI3K/AKT/mTOR. It is thus important to have a better understanding of the molecular resistance mechanisms to improve patient survival benefit from…

    Juga tersedia di: PLOS

  3. Artikel Jurnal

    Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease

    Mary T. Scott; Wei Liu; Rebecca Mitchell dkk.

    Nature Communications, Vol. 15 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Whilst it is recognised that targeting self-renewal is an effective way to functionally impair the quiescent leukaemic stem cells (LSC) that persist as residual disease in chronic myeloid leukaemia (CML), developing therapeutic strategies to achieve this have proved challenging. We…

  4. Artikel Jurnal

    MDM2 Antagonists Counteract Drug-Induced DNA Damage

    Anna E. Vilgelm; Priscilla Cobb; Kiran Malikayil dkk.

    EBioMedicine, Vol. 24 No. C · 2017 · Inggris · DOAJ Scopus

    Antagonists of MDM2-p53 interaction are emerging anti-cancer drugs utilized in clinical trials for malignancies that rarely mutate p53, including melanoma. We discovered that MDM2-p53 antagonists protect DNA from drug-induced damage in melanoma cells and patient-derived xenografts. Among the tested…

  5. Artikel Jurnal

    Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

    Srdan Verstovsek; Lynda Foltz; Vikas Gupta dkk.

    Haematologica, Vol. 108 No. 10 · 2023 · Inggris · DOAJ Scopus

    Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant form of PTX-2 that has shown preclinical…

  6. Artikel Jurnal

    BRD4-mediated repression of p53 is a target for combination therapy in AML

    Anne-Louise Latif; Ashley Newcombe; Sha Li dkk.

    Nature Communications, Vol. 12 No. 1 · 2021 · Inggris · DOAJ Scopus

    MDM2 and BET inhibitors have shown efficacy in AML treatment. Here, the authors show that the two compounds can synergize through both p53 protein stabilization and inhibition of BRD4-mediated repression of p53 target genes.